Regulation & Compliance

A new study aims to confirm a novel immunotherapy's dramatic results in colorectal cancer, offering hope for patients with limited treatment options.

Forum Investment Group hires Ares vet Grant Turner in a strategic bid to scale its 1031 exchange platform and capture the booming tax-advantaged market.

Snack giant Our Home unveils a strategic pivot at Expo West, doubling down on protein and avocado oil to capture the modern, health-conscious consumer.

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.

Monjur's new AI platform, supervised by attorneys, promises to speed up deals and cut legal risks for Managed Service Providers.

After a major turnaround, Genetix Biotherapeutics announces its first profitable quarter and plans to double production of its high-stakes gene therapies.

French giant Efor deepens its North American footprint, acquiring CQV specialist DynamixE to target the complex cell and gene therapy manufacturing market.

The EHR vendor will showcase how its 'intelligent interoperability' uses AI and patient control to move beyond compliance and create strategic advantages.

Texans Credit Union merges with Las Colinas Federal Credit Union, adding 10,000 members and expanding its footprint in a competitive North Texas market.

The Advertising Research Foundation marks 90 years by tackling AI's impact on media, reaffirming its mission to ground innovation in scientific trust.

A breakthrough quantum algorithm could shatter global encryption years ahead of schedule, forcing an urgent race to secure our digital world from a new threat.

Regulatory delays in China scuttled Pulmatrix's merger with Cullgen, forcing the biotech to urgently seek new partners for its promising drug pipeline.

As AI reshapes medicine, Seoul prepares to host global experts to explore its vast potential and critical challenges in healthcare and medical tourism.

With a $41M boost from a16z, Ease Health is using AI to unify a fractured behavioral health system, promising relief for overwhelmed providers.

Avenacy launches its 26th product, a generic Benadryl injection, tackling drug shortages and aiming to improve patient safety with unique packaging.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

A new era in hearing arrives with Cochlear's Nexa System, the world's first upgradeable implant, tackling India's vast auditory health challenges.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

Neogen divests its pioneering genomics business for $160M to slash debt, while Zoetis bolsters its dominance in the animal health diagnostics market.